{"entity":{"id":"nct06243354","kind":"trial","name":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation","aka":[],"tldr":"A phase 1/2 trial of Test product: HYP-2090PTSA in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.","summary":"Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation is a phase 1/2 interventional study registered as NCT06243354 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 257 participants planned, started 2024-02-04 and due to reach its primary completion in 2026-12. Interventions recorded: Test product: HYP-2090PTSA.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06243354","url":"https://clinicaltrials.gov/study/NCT06243354"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06243354","phase":"1/2","setting":"An Open-label, Multi-center, Multi-cohort, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HYP-2090PTSA in Patients With Advanced Solidt Tumors Harboring KRAS Mutation","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","enrolled":257,"outcomes":[]},"route":"/trials/nct06243354/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}